Oseltamivir (GS-4104) is an antiviral prodrug targeted against the influenza viruses. Oseltamivir acid is the active metabolite of oseltamivir. It acts as an inhibitor of influenza neuraminidases A and B (IC50 = 0.1 to 4.9 nM for both enzymes), in this way preventing virus budding and release.
Oseltamivir Acid is a metabolite of Oseltamivir (O701000).
Oseltamivir Acid (Oseltamivir EP Impurity C) is a metabolite of Oseltamivir (O701000). It is a COVID19-related research product.
ChEBI: A cyclohexenecarboxylic acid that is cyclohex-1-ene-1-carboxylic acid which is substituted at positions 3, 4, and 5 by pentan-3-yloxy, acetamido, and amino groups, respectively (the 3R,4R,5S enantiomer). A
antiviral drug, it is used as the corresponding ethyl ester prodrug, oseltamivir, to slow the spread of influenza.
[1] enguang feng, deju ye, jian li, dengyou zhang, jinfang wang, fei zhao, rolf hilgenfeld, mingyue zheng, hualiang jiang and hong liu. recent advances in neuraminidase inhibitor development as anti-influenza drugs. chem med chem 2012, 7: 1527 – 1536.
[2] tom jefferson reviewer, mark jones, peter doshi, elizabeth a spencer, igho onakpoya, carl j heneghan. oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comment. bmj. 2014, 348: g2545.
[3] rashmi dixit, gulam khandaker, scott ilgoutz, harunor rashid and robert booy. emergence of oseltamivir resistance: control and management of influenza before, during and after the pandemic. infectious disorders – drug targets. 2013, 13 (1): 34-45.
